{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04092673",
            "orgStudyIdInfo": {
                "id": "eFT226-0002"
            },
            "organization": {
                "fullName": "Effector Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies",
            "officialTitle": "A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies",
            "acronym": "Zotatifin",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-in-subjects-with-selected-advanced-solid-tumor-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-10-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-09-10",
            "studyFirstSubmitQcDate": "2019-09-13",
            "studyFirstPostDateStruct": {
                "date": "2019-09-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Effector Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.",
            "detailedDescription": "Part 1 (Dose Escalation): Completed; Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) identified\n\nPart 1a (Dose Escalation) This cohort will enroll patients with an advanced breast cancer that is refractory or intolerant to SOC therapy.\n\nPart 1b (Dose Escalation) This cohort will enroll patients with an advanced breast cancer that is refractory or intolerant to SOC therapy.\n\nPart 2 (Expansion Cohort) provides defined expansion cohorts to further explore the safety, pharmacology, and clinical activity of eFT226 monotherapy and in various combinations in subjects with previously treated advanced solid tumor malignancies."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Adult"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Dose Escalation, 3+3, 3+3+3",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: Sequential escalation (Completed)",
                    "type": "EXPERIMENTAL",
                    "description": "eFT226 administered IV weekly in 21-day cycles; dose escalated in sequential cohorts after subjects enrolled in a given cohort have completed DLT evaluation period.",
                    "interventionNames": [
                        "Drug: eFT226"
                    ]
                },
                {
                    "label": "Part 2: Cohort Expansion, Monotherapy, NSCLC, KRAS (EMNK)",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort EMNK",
                    "interventionNames": [
                        "Drug: eFT226"
                    ]
                },
                {
                    "label": "Part 2: Cohort Expansion, Monotherapy, Breast, FGFR (EMBF)",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort EMBF",
                    "interventionNames": [
                        "Drug: eFT226"
                    ]
                },
                {
                    "label": "Part 2: Cohort Expansion, Monotherapy, Breast, HER2 (EMBH)",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort EMBH",
                    "interventionNames": [
                        "Drug: eFT226"
                    ]
                },
                {
                    "label": "Part 2: Cohort Expansion, Combination, Breast, Fulvestrant (ECBF)",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort ECBF; Combination therapy partner administered per SOC at the approved dose.",
                    "interventionNames": [
                        "Drug: Fulvestrant"
                    ]
                },
                {
                    "label": "Part 2: Cohort Expansion, Combination, NSCLC, Sotorasib (ECNS)",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort ECNS; Combination therapy partner administered per SOC at the approved dose.",
                    "interventionNames": [
                        "Drug: Sotorasib"
                    ]
                },
                {
                    "label": "Part 2: Cohort Expansion, Combination, Breast, Fulvestrant+Abemaciclib (ECBF+A)",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort ECBF+A; Combination therapy partner administered per SOC at the approved dose.",
                    "interventionNames": [
                        "Drug: Fulvestrant",
                        "Drug: Abemaciclib"
                    ]
                },
                {
                    "label": "Part 2: Cohort Expansion, Combination, Breast, Trastuzumab (ECBT)",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort ECBT; Combination therapy partner administered per SOC at the approved dose.",
                    "interventionNames": [
                        "Drug: Trastuzumab"
                    ]
                },
                {
                    "label": "Part 1a: Dose Escalation, Combination, Breast",
                    "type": "EXPERIMENTAL",
                    "description": "eFT226 administered IV weekly in 21-day cycles. Fulvestrant will also be given. Dose escalations per protocol.",
                    "interventionNames": [
                        "Drug: Fulvestrant"
                    ]
                },
                {
                    "label": "Part 1b Dose Escalation, Combination, Breast",
                    "type": "EXPERIMENTAL",
                    "description": "eFT226 administered IV every other week in 14-day cycles. Fulvestrant will also be given. Dose escalations per protocol.",
                    "interventionNames": [
                        "Drug: Fulvestrant"
                    ]
                },
                {
                    "label": "Part 2 Cohort Expansion, Combination, Breast, Fulvestrant, Cyclin D1",
                    "type": "EXPERIMENTAL",
                    "description": "ECBF-D1; Combination therapy partner administered per SOC at the approved dose.",
                    "interventionNames": [
                        "Drug: Fulvestrant"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "eFT226",
                    "description": "eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).",
                    "armGroupLabels": [
                        "Part 1: Sequential escalation (Completed)",
                        "Part 2: Cohort Expansion, Monotherapy, Breast, FGFR (EMBF)",
                        "Part 2: Cohort Expansion, Monotherapy, Breast, HER2 (EMBH)",
                        "Part 2: Cohort Expansion, Monotherapy, NSCLC, KRAS (EMNK)"
                    ],
                    "otherNames": [
                        "Selective translation inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Sotorasib",
                    "description": "Recommended dosage: 960 mg orally once daily",
                    "armGroupLabels": [
                        "Part 2: Cohort Expansion, Combination, NSCLC, Sotorasib (ECNS)"
                    ],
                    "otherNames": [
                        "Lumarkus"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fulvestrant",
                    "description": "500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter",
                    "armGroupLabels": [
                        "Part 1a: Dose Escalation, Combination, Breast",
                        "Part 1b Dose Escalation, Combination, Breast",
                        "Part 2 Cohort Expansion, Combination, Breast, Fulvestrant, Cyclin D1",
                        "Part 2: Cohort Expansion, Combination, Breast, Fulvestrant (ECBF)",
                        "Part 2: Cohort Expansion, Combination, Breast, Fulvestrant+Abemaciclib (ECBF+A)"
                    ],
                    "otherNames": [
                        "Faslodex"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Abemaciclib",
                    "description": "Dose in combination with fulvestrant: 150 mg twice daily",
                    "armGroupLabels": [
                        "Part 2: Cohort Expansion, Combination, Breast, Fulvestrant+Abemaciclib (ECBF+A)"
                    ],
                    "otherNames": [
                        "Verzenia"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Trastuzumab",
                    "description": "600 mg every 3 weeks",
                    "armGroupLabels": [
                        "Part 2: Cohort Expansion, Combination, Breast, Trastuzumab (ECBT)"
                    ],
                    "otherNames": [
                        "Herceptin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Parts 1a and 1b: MTD",
                    "description": "determined by occurrence of first cycle DLTs within a 3+3 or 3+3+3 clinical trial design",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Parts 1a and 1b; incidence of AEs, serious adverse events (SAEs), and DLTs",
                    "description": "according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Parts 1a and 1b: RP2D",
                    "description": "determined by Incidence and type of DLTs",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Parts 1a and 1b: RP2D",
                    "description": "determine by Incidence, type, and severity of AEs and SAEs graded as per NCI CTCAE",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: Objective Response Rate- Efficacy",
                    "description": "defined as confirmed Complete Response (CR) or Partial Response (PR)",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: (Combination Cohorts) Determine MTD",
                    "description": "determined by occurrence of first cycle Dose Limiting Toxicities (DLTs) within the study design",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: (Combination Cohorts) Incidence, type, and severity of AEs and SAEs",
                    "description": "via adverse event monitoring",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: (Combination Cohorts) Determine RP2D",
                    "description": "determined by incidence and type of DLTs, and incidence, type, and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: Percent change in tumor dimensions of target lesions- Efficacy",
                    "description": "calculated by the percentage change from baseline in the sum of the LD of target lesions",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: Time to Response (TTR)- Efficacy",
                    "description": "defined as the interval from the start of study therapy to the first documentation of an objective response",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: Duration of Response (DOR)- Efficacy",
                    "description": "defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause",
                    "timeFrame": "Through study completion, approximately 12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Parts 1a and 1b: Objective response",
                    "description": "determined by confirmed CR or PR",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Parts 1a and 1b: Percent change in tumor dimensions of target lesions",
                    "description": "calculated by the percentage change from baseline in the sum of the LD of target lesions",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Parts 1a and 1b: TTR",
                    "description": "defined as the interval from the start of study therapy to the first documentation of an objective response",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Parts 1a and 1b: DOR",
                    "description": "defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Parts 1a and 1b: PFS",
                    "description": "defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: (Monotherapy and Combination Cohorts) Incidence and severity of AEs, SAEs, and additional safety parameters",
                    "description": "via adverse event monitoring",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Part 2: Progression Free Survival",
                    "description": "defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Evaluate plasma Pharmacokinetic (PK) parameters of eFT226",
                    "description": "including area under the plasma concentration-time curve",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Evaluate plasma Pharmacokinetic (PK) parameters of eFT226",
                    "description": "including maximum concentration",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Evaluate plasma Pharmacokinetic (PK) parameters of eFT226",
                    "description": "including terminal phase rate constant",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Evaluate plasma Pharmacokinetic (PK) parameters of eFT226",
                    "description": "including estimated steady-state volume of distribution \\[Vss\\]",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Evaluate plasma Pharmacokinetic (PK) parameters of eFT226",
                    "description": "including half-life (t\u00bd)",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Evaluate plasma Pharmacokinetic (PK) parameters of eFT226",
                    "description": "including total body clearance",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Evaluate plasma Pharmacokinetic (PK) parameters of eFT226including terminal state volume of distribution",
                    "description": "including terminal state volume of distribution",
                    "timeFrame": "Through study completion, approximately 12 months"
                },
                {
                    "measure": "Evaluate plasma Pharmacokinetic (PK) parameters of eFT226 including terminal phase rate constant",
                    "description": "including terminal phase rate constant",
                    "timeFrame": "Through study completion, approximately 12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Criteria:\n\nParts 1a and 1b (Dose Escalation + Fulvestrant):\n\n* Patient has histological or cytological confirmation of breast cancer.\n* Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit.\n* Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:\n\n  * Minimum of one prior line of therapy for advanced/metastatic disease.\n  * Maximum of five prior lines of therapy for advanced/metastatic disease.\n  * Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.\n  * Prior treatment has included a CDK4/6 inhibitor.\n* Tumor is ER+ (defined as ER IHC staining \\> 0%).\n\nCohort EMNK:\n\n* Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate.\n* Tumor has a known KRAS-activating mutation; Patients with KRAS G12C mutations are excluded.\n\nCohort EMBF:\n\n* Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:\n\n  * Minimum of one prior line of therapy for advanced/metastatic disease.\n  * Maximum of five prior lines of therapy for advanced/metastatic disease.\n  * Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting, which may include combination therapy (eg, with a CDK4/6 inhibitor).\n* Tumor is ER+ (defined as ER IHC staining \\> 0%) and has FGFR amplification.\n\nCohort EMBH:\n\n* Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:\n\n  * Minimum of one prior line of therapy for advanced/metastatic disease.\n  * Minimum of one line of HER2-directed therapy Note: Prior treatment with CDK4/6 inhibitors is permitted.\n* Tumor is ER+ (defined as ER IHC staining \\> 0%) and HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+).\n\nCohort ECNS:\n\n* Patient has histologically or cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC.\n* Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate. Note: Patients who have declined approved therapy(ies) or who per treating physician are not eligible for approved therapy(ies) (eg, due to intolerance) may be eligible following discussion with the Medical Monitor.\n* Tumor has a known G12C KRAS-activating mutation. Note: Patients who have been previously treated with KRAS-specific therapy are excluded.\n\nCohort ECBF:\n\n* Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:\n\n  * Minimum of one prior line of therapy for advanced/metastatic disease.\n  * Maximum of five prior lines of therapy for advanced/metastatic disease.\n  * Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.\n  * Prior treatment has included a CDK4/6 inhibitor.\n* Tumor is ER+ (defined as ER IHC staining \\> 0%).\n\nCohort ECBF+A:\n\n* Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:\n\n  * Minimum of one prior line of therapy for advanced/metastatic disease.\n  * Maximum of five prior lines of therapy for advanced/metastatic disease.\n  * Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.\n* Tumor is ER+ (defined as ER IHC staining \\> 0%) and HER2- (defined as absence of HER2 3+ IHC staining and/or absence of FISH+).\n\nCohort ECBT:\n\n* Patient has progressed after treatment with at least one approved anti-HER2 agent and has been administered at least one line of chemotherapy.\n* Tumor is HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+). Cohorts EMBF, EMBH, ECBF, ECBF+A: There is no limit on the number of lines of prior endocrine therapies.\n\nCohort ECBF-D1:\n\n* Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit.\n* Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:\n\n  * Minimum of one prior line of therapy for advanced/metastatic disease.\n  * Maximum of five prior lines of therapy for advanced/metastatic disease.\n  * Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.\n  * Prior treatment has included a CDK4/6 inhibitor.\n* Tumor is ER+ (defined as ER IHC staining \\> 0%).\n* Tumor has amplification of Cyclin D1 as determined by next generation sequencing or in situ hybridization.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mark Densel",
                    "role": "CONTACT",
                    "phone": "858-925-8215",
                    "email": "clinicaltrials@effector.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Douglas Warner, MD",
                    "affiliation": "EFFECTOR Therapeutics, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Southern California",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Xiomara Menendez",
                            "role": "CONTACT",
                            "phone": "323-409-4638",
                            "email": "menendez_x@med.usc.edu"
                        },
                        {
                            "name": "Anthony El-Khoueiry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Valkyrie Clinical Trials",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90067",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chemyn Cortez",
                            "role": "CONTACT",
                            "phone": "559-360-3707",
                            "email": "chemyn.cortez@valkyrieclinicaltrials.com"
                        },
                        {
                            "name": "David Berz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Hoag Memorial Hospital Presbyterian",
                    "status": "COMPLETED",
                    "city": "Newport Beach",
                    "state": "California",
                    "zip": "92663",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.61891,
                        "lon": -117.92895
                    }
                },
                {
                    "facility": "Stanford University",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kaushali Thakore-Shah",
                            "role": "CONTACT",
                            "email": "kthakore@stanford.edu"
                        },
                        {
                            "name": "Jennifer Caswell-Jin, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                },
                {
                    "facility": "START Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Abigail Van Kirk",
                            "role": "CONTACT",
                            "phone": "616-954-5550",
                            "phoneExt": "1824",
                            "email": "abigail.vankirk@startmidwest.com"
                        },
                        {
                            "name": "Manish Sharma, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "Comprehensive Cancer Centers of Nevada",
                    "status": "COMPLETED",
                    "city": "Las Vegas",
                    "state": "Nevada",
                    "zip": "89169",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.17497,
                        "lon": -115.13722
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center- Monmouth",
                    "status": "RECRUITING",
                    "city": "Middletown",
                    "state": "New Jersey",
                    "zip": "07748",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ezra Rosen",
                            "role": "CONTACT",
                            "email": "rosene1@mskcc.org"
                        },
                        {
                            "name": "Colleen Wenzel",
                            "role": "CONTACT",
                            "email": "WenzelC1@mskcc.org"
                        },
                        {
                            "name": "Ezra Rosen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.39652,
                        "lon": -74.09211
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center- Commack",
                    "status": "RECRUITING",
                    "city": "Commack",
                    "state": "New York",
                    "zip": "11725",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ezra Rosen, MD",
                            "role": "CONTACT",
                            "email": "rosene1@mskcc.org"
                        },
                        {
                            "name": "Colleen Wenzel",
                            "role": "CONTACT",
                            "email": "WenzelC1@mskcc.org"
                        },
                        {
                            "name": "Ezra Rosen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84288,
                        "lon": -73.29289
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center- Westchester",
                    "status": "RECRUITING",
                    "city": "Harrison",
                    "state": "New York",
                    "zip": "10604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ezra Rosen",
                            "role": "CONTACT",
                            "email": "rosene1@mskcc.org"
                        },
                        {
                            "name": "Colleen Wenzel",
                            "role": "CONTACT",
                            "email": "WenzelC1@mskcc.org"
                        },
                        {
                            "name": "Ezra Rosen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.96899,
                        "lon": -73.71263
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "11101",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ezra Rosen, MD",
                            "role": "CONTACT",
                            "email": "rosene1@mskcc.org"
                        },
                        {
                            "name": "Colleen Wenzel",
                            "role": "CONTACT",
                            "email": "WenzelC1@mskcc.org"
                        },
                        {
                            "name": "Ezra Rosen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of Toledo Medical Center",
                    "status": "COMPLETED",
                    "city": "Toledo",
                    "state": "Ohio",
                    "zip": "43614",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.66394,
                        "lon": -83.55521
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amanda Ekert",
                            "role": "CONTACT",
                            "phone": "713-745-8074",
                            "email": "ACEckert@mdanderson.org"
                        },
                        {
                            "name": "Funda Meric-Bernstam, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "New Experimental Therapeutics of San Antonio - NEXT Oncology",
                    "status": "COMPLETED",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Karina Castillo-Grady",
                            "role": "CONTACT",
                            "phone": "703-280-5390",
                            "email": "Karina.CastilloGrady@usoncology.com"
                        },
                        {
                            "name": "Alexander Spira, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "There is not a plan to make IPD available"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068878",
                    "term": "Trastuzumab"
                },
                {
                    "id": "C000706028",
                    "term": "Sotorasib"
                },
                {
                    "id": "D000077267",
                    "term": "Fulvestrant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000065171",
                    "term": "Estrogen Receptor Antagonists"
                },
                {
                    "id": "D000004965",
                    "term": "Estrogen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1723",
                    "name": "Fulvestrant",
                    "asFound": "Challenge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M325",
                    "name": "Trastuzumab",
                    "asFound": "Follow-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M96444",
                    "name": "Sotorasib",
                    "asFound": "Retinal Vein",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6263",
                    "name": "Coal Tar",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M8114",
                    "name": "Estrogen Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30483",
                    "name": "Estrogen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}